Definium Therapeutics (DFTX) Total Current Liabilities (2020 - 2026)

Definium Therapeutics (DFTX) has reported Total Current Liabilities for 7 consecutive years, with $81.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 166.11% year-over-year to $81.1 million; the TTM figure through Mar 2026 stood at $81.1 million (up 166.11% YoY), while the FY2025 annual figure was $66.7 million, up 71.69% from the prior year.
• Total Current Liabilities advanced to $81.1 million in Q1 2026 per DFTX's latest filing, from $66.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $81.1 million in Q1 2026 and bottomed at $7.9 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $38.0 million across 5 years, with a median of $33.3 million in 2024.
• Annual changes were most pronounced in 2023 — Total Current Liabilities surged 346.21% — and 2025, when it sank 53.3%.
• Definium Therapeutics' Total Current Liabilities stood at $17.9 million in 2022, then surged by 80.23% to $32.2 million in 2023, then climbed by 20.48% to $38.8 million in 2024, then soared by 71.69% to $66.7 million in 2025, then rose by 21.61% to $81.1 million in 2026.
• Business Quant data shows DFTX's Total Current Liabilities at $81.1 million in Q1 2026, $66.7 million in Q4 2025, and $65.4 million in Q3 2025.